The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Penile Induration

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Penile Induration


Psychiatry related information on Penile Induration

  • CONCLUSIONS: The use of colchicine plus vitamin E during the early stages of Peyronie's disease (time from onset < 6 months) in patients with penile curvature of < 30 degrees and no erectile dysfunction is an effective and well-tolerated way to stabilize the disease [5].
  • PATIENTS AND METHODS: Fifty consecutive patients (age 35-75 years) with Peyronie's disease who were considered suitable for surgical treatment were investigated using CDI to determine the haemodynamic variables of penile vasculature after an intracorporeal injection of 20 microg of alprostadil (with manual self-stimulation) [6].

High impact information on Penile Induration


Chemical compound and disease context of Penile Induration


Biological context of Penile Induration


Anatomical context of Penile Induration


Gene context of Penile Induration


Analytical, diagnostic and therapeutic context of Penile Induration


  1. Isolation and characterization of collagen in Peyronie's disease. Somers, K.D., Sismour, E.N., Wright, G.L., Devine, C.J., Gilbert, D.A., Horton, C.E. J. Urol. (1989) [Pubmed]
  2. The genetic and bacteriological aspects of Peyronie's disease. Ralph, D.J., Schwartz, G., Moore, W., Pryor, J.P., Ebringer, A., Bottazzo, G.F. J. Urol. (1997) [Pubmed]
  3. Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie's disease. Chiang, P.H., Chiang, C.P., Shen, M.R., Huang, C.H., Wang, C.J., Huang, I.Y., Shieh, T.Y. Eur. Urol. (1992) [Pubmed]
  4. Tissue engineering in urology: where are we going? Metwalli, A.R., Colvert, J.R., Kropp, B.P. Current urology reports. (2003) [Pubmed]
  5. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. Prieto Castro, R.M., Leva Vallejo, M.E., Regueiro Lopez, J.C., Anglada Curado, F.J., Alvarez Kindelan, J., Requena Tapia, M.J. BJU international. (2003) [Pubmed]
  6. The role of colour Doppler imaging in the management of Peyronie's disease. Ahmed, M., Chilton, C.P., Munson, K.W., Williams, J.H., Pallan, J.H., Turner, G. British journal of urology. (1998) [Pubmed]
  7. Peyronie's disease in association with metoprolol. Yudkin, J.S. Lancet (1977) [Pubmed]
  8. Propranolol and Peyronie's disease. Wallis, A.A., Bell, R., Sutherland, P.W. Lancet (1977) [Pubmed]
  9. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. Di Stasi, S.M., Giannantoni, A., Stephen, R.L., Capelli, G., Giurioli, A., Jannini, E.A., Vespasiani, G. J. Urol. (2004) [Pubmed]
  10. Experience with intraplaque injection of verapamil for Peyronie's disease. Levine, L.A., Goldman, K.E., Greenfield, J.M. J. Urol. (2002) [Pubmed]
  11. Results of radiotherapy and vitamin E in the treatment of Peyronie's disease. Rodrigues, C.I., Njo, K.H., Karim, A.B. Int. J. Radiat. Oncol. Biol. Phys. (1995) [Pubmed]
  12. Tamoxifen versus placebo in the treatment of Peyronie's disease. Teloken, C., Rhoden, E.L., Grazziotin, T.M., Ros, C.T., Sogari, P.R., Souto, C.A. J. Urol. (1999) [Pubmed]
  13. Treatment of Peyronie's disease with intralesional verapamil injection. Levine, L.A. J. Urol. (1997) [Pubmed]
  14. Penile vascular assessment using color duplex sonography in men with Peyronie's disease. Levine, L.A., Coogan, C.L. J. Urol. (1996) [Pubmed]
  15. Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease. Hauck, E.W., Hauptmann, A., Schmelz, H.U., Bein, G., Weidner, W., Hackstein, H. J. Urol. (2003) [Pubmed]
  16. Humoral immune responses in Peyronie's disease patients receiving clostridial collagenase therapy. Hamilton, R.G., Mintz, G.R., Gelbard, M.K. J. Urol. (1986) [Pubmed]
  17. HLA association of idiopathic Peyronie's disease: an indication of autoimmune phenomena in etiopathogenesis? Rompel, R., Weidner, W., Mueller-Eckhardt, G. Tissue Antigens (1991) [Pubmed]
  18. Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease. Lin, C.S., Lin, G., Wang, Z., Maddah, S.A., Lue, T.F. Biochem. Biophys. Res. Commun. (2002) [Pubmed]
  19. Wogonin suppresses cellular proliferation and expression of monocyte chemoattractant protein 1 in Peyronie's plaque-derived cells. Wang, Z., Lin, G., Lue, T.F., Lin, C.S. BJU international. (2003) [Pubmed]
  20. The immunological features of Peyronie's disease. Ralph, D.J., Mirakian, R., Pryor, J.P., Bottazzo, G.F. J. Urol. (1996) [Pubmed]
  21. Anatomy and pathophysiology of Peyronie's disease and congenital deviation of the penis. Schubert, G.E. Urologia internationalis. (1991) [Pubmed]
  22. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Duncan, M.R., Berman, B., Nseyo, U.O. Scandinavian journal of urology and nephrology. (1991) [Pubmed]
  23. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. El-Sakka, A.I., Hassoba, H.M., Pillarisetty, R.J., Dahiya, R., Lue, T.F. J. Urol. (1997) [Pubmed]
  24. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. El-Sakka, A.I., Hassoba, H.M., Chui, R.M., Bhatnagar, R.S., Dahiya, R., Lue, T.F. J. Urol. (1997) [Pubmed]
  25. HLA-A and B antigens in patients with Peyronie disease. Deguchi, T., Maeda, S., Sakai, S., Kuriyama, M., Kawada, Y., Nishiura, T. Urology (1984) [Pubmed]
  26. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Davila, H.H., Magee, T.R., Zuniga, F.I., Rajfer, J., Gonzalez-Cadavid, N.F. Urology (2005) [Pubmed]
  27. Iontophoresis for treatment of Peyronie's disease. Riedl, C.R., Plas, E., Engelhardt, P., Daha, K., Pflüger, H. J. Urol. (2000) [Pubmed]
  28. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. Ahuja, S., Bivalacqua, T.J., Case, J., Vincent, M., Sikka, S.C., Hellstrom, W.J. J. Androl. (1999) [Pubmed]
  29. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Weidner, W., Hauck, E.W., Schnitker, J. Eur. Urol. (2005) [Pubmed]
  30. Penile prosthetic surgery for Peyronie's disease: defining the need for intraoperative adjuvant maneuvers. Mulhall, J., Ahmed, A., Anderson, M. The journal of sexual medicine. (2004) [Pubmed]
WikiGenes - Universities